Ironwood Pharmaceuticals (NASDAQ:IRWD): The mean estimate for the short term price target for Ironwood Pharmaceuticals (NASDAQ:IRWD) stands at $12.57 according to 7 Analysts. The higher price target estimate for the stock has been calculated at $16 while the lower price target estimate is at $10.
Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, Cowen & Company upgrades its outlook on Ironwood Pharmaceuticals (NASDAQ:IRWD). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Market Perform. The rating by the firm was issued on April 6, 2016. Company shares have received an average consensus rating of Hold for the current week
On the companys insider trading activities,The director of Ironwood Pharmaceuticals Inc, Olanoff Lawrence S sold 2,200 shares at $12.92 on June 3, 2016. The Insider selling transaction had a total value worth of $28,424. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Ironwood Pharmaceuticals (NASDAQ:IRWD) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.12 points or 0.93% at $12.75 with 877,900 shares getting traded. Post opening the session at $12.77, the shares hit an intraday low of $12.715 and an intraday high of $13.06 and the price was in this range throughout the day. The company has a market cap of $1,844 million and the number of outstanding shares have been calculated to be 144,604,310 shares. The 52-week high of Ironwood Pharmaceuticals (NASDAQ:IRWD) is $13.27 and the 52-week low is $7.35.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.